Skip to main content
. 2023 Sep 14;58(12):1237–1251. doi: 10.1007/s00535-023-02038-y

Table 3.

Clinical characteristics and pathological changes in the livers of 70 NASH patients

Paramter NASH
ANA(−) (n = 36) ANA(+) (n = 20) AIH-overlap (n = 14)
IAIHG score
 ≥ 15 (definite AIH) 0 (0%) 0 (0%) 14 (100%) ††‡‡
 10–15 (probable AIH) 13 (36.1%) 20 (100%) 0 (0%)
  < 10 23 (63.9%) 0 (0%) 0 (0%)
Age (years) 51.5 (40.8–66.3) 58.5 (53.3–67.3) 59 (39.8–68.5)
Male sex (%) 58.3 25 † 14.3 †
BMI (kg/m2) 28.7 (25.8–31.5) 28.2 (23.9–32.2) 26.9 (23.6–30.3)
Albumin (g/dL) 4.2 (3.7–4.5) 4.1 (4.0–4.2) 4.0 (3.8–4.4)
AST (U/L) 46 (36.5–70.5) 51.5 (42.8–77.3) 82 (59–87.3) †
ALT (U/L) 68.5 (47.5–108.3) 70.5 (47.5–126.0) 66 (64.5–90.5)
GGT (U/L) 58 (41.8–80.5) 59 (34.0–88.5) 61.5 (41.8–138.8)
Total bilirubin (mg/dL) 0.75 (0.60–1.00) 0.8 (0.70–1.10) 0.85 (0.68–0.93)
HDL-C (mg/dL) 46.0 (40.4–53.5) 57.7 (47.6–69.5) † 53.8 (49.0–58.5)
LDL-C (mg/dL) 119 (97–135) 109.5 (95.0–127.3) 100.5 (88.0–153.0)
Triglycerides (mg/dL) 116 (90.5–175.0) 103 (74.3–134.8) 117 (110.5–127.3)
Creatinine (mg/dL) 0.72 (0.56–0.87) 0.69 (0.57–0.81) 0.57 (0.56–0.60)
CRP (mg/dL) 0.12 (0.10–0.28) 0.10 (0.07–0.26) 0.12 (0.07–0.51)
Platelet count (10,000/µl) 21.6 (17.3–28.0) 21.1 (20.1–27.7) 15.6 (14.4–20.7)
Prothrombin time (%) 100 (94.5–100.0) 100 (100–100) 100 (100–100)
FBG (mg/dL) 97 (86.3–115.5) 98 (86.5–107.5) 91 (81.0–104.5)
HbA1c (N) 6.1 (5.6–7.2) 6.1 (5.9–6.9) 6 (5.5–6.1)
ANA
 Negative (%) 36 (100%) 0 (0%) †† 2 (14.2%) ††
 Positive (%) 0 (0%) 20 (100%) 12 (85.8%)
  ≧ 1:40 (%) 0 (0%) 17 (85%) 5 (41.7%)
  ≧ 1:320 (%) 0 (0%) 3 (15%) 4 (33.3%)
  ≧ 1:2560 (%) 0 (0%) 0 (0%) 3 (25%)
AMA-M2 (index) 0.55 (0.50–0.95) 1.4 (0.8–1.7) † 1.7 (1.65–2.20) ††‡
IgA (mg/dL) 230.5 (202.0–306.5) 280.5 (233.0–356.3) 255 (214.5–451.5)
IgG (mg/dL) 1189 (1049.0–1338.5) 1360 (1159.0–1575.5) † 1611 (1429.8–1922.3) ††
IgM (mg/dL) 80.5 (57.8–111.0) 93 (58.3–139.3) 133 (121.8–153.0) ††‡
Hyaluronic acid (ng/mL) 37.5 (11.9–60.1) 50.2 (26.4–82.1) 109.8 (66.1–152.0) †
Liver Stiffness (kPa) 10.2 (8.5–13.2) 8.1 (6.8–10.3) 10 (6.2–15.9)
CAP (dB/m) 306.5 (274.8–338.5) 313.5 (273.3–342.0) 257 (203.8–319.5) †‡
NAS
 Steatosis
  0 0 (0%) 0 (0%) 0 (0%) †‡
  1 18 (50%) 8 (40%) 10 (71.4%)
  2 11 (30.6%) 10 (50%) 4 (28.6%)
  3 7 (19.4%) 2 (10%) 0 (0%)
 Lobular inflammation
  0 1 (2.8%) 0 (0%) 0 (0%)
  1 19 (52.7%) 10 (50%) 5 (35.7%)
  2 15 (41.7%) 10 (50%) 9 (64.3%)
  3 1 (2.8%) 0 (0%) 0 (0%)
 Ballooning
  0 0 (0%) 0 (0%) 0 (0%)
  1 26 (72.2%) 15 (75%) 8 (57.1%)
  2 10 (27.8%) 5 (25%) 6 (42.9%)
 Fibrosis
  0 0 (0%) 2 (10%) 0 (0%) ‡
  1 17 (47.2%) 9 (45%) 1 (7.2%)
   1A 13 (76.5%) 4 (20%) 0 (0%)
   1B 4 (23.5%) 5 (25%) 1 (7.2%)
   1C 0 (0%) 0 (0%) 0 (0%)
  2 5 (13.9%) 6 (30%) 3 (21.4%)
  3 11 (30.6%) 3 (15%) 10 (71.4%)
  4 3 (8.3%) 0 (0%) 0 (0%)

Bold values indicate the parameter significantly changes between AIH-overlap and ANA -/+ NASH patients

p < 0.05 compared with ANA(−), ††p < 0.001 compared with ANA(-)

p < 0.05 AIH-overlap compared with ANA( +), ‡‡p < 0.001 AIH-overlap compared with ANA( +)

Values are presented as N, N (%), or median (P25–P75)